Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU

详细信息    查看全文

• 作者：Katherine A. Lyseng-Williamson ; Sheridan M. Hoy
• 刊名：Drugs & Therapy Perspectives
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：31
• 期：6
• 页码：190-195
• 全文大小：422 KB
• 参考文献：1.Baker DP, Pepinsky RB, Brickelmaier M, et al. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):777-5.View Article PubMed
  2.Kieseier BC, Calabresi PA. PEGylation of interferon-beta-1a: a promising strategy in multiple sclerosis. CNS Drugs. 2012;26(3):205-4.View Article PubMed
  3.Girouard N, Soucy N. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence. 2011;5:101-.PubMed Central PubMed
  4.Plegridy solution for injection: summary of product characteristics. London: European Medicines Agency; 2015.
  5.Plegridy (peginterferon beta-1a), for subcutaneous injection: US prescribing information. Cambridge (MA): Biogen Idec Inc.; 2014.
  6.Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657-5.View Article PubMed
  7.Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2014. doi:10.-177/-352458514557986-/span> .
  8.Plegridy: assessment report. London: European Medicines Agency; 2014.
  9.Tolley K, Hutchinson M, Pachner A, et al. Systematic literature review and network meta-analysis of peginterferon beta-1a and injectable therapies for relapsing–remitting multiple sclerosis [abstract no. P318 plus poster]. Mult Scler J. 2014;20(Suppl 1):209.
  10.Kinter ET, Guo S, Altincatal A, et al. Impact of treatment-related flu-like symptoms and injection site reactions on quality of life in patients with multiple sclerosis: ADVANCE study [abstract no. 799 plus poster]. Mult Scler J. 2014;20(Suppl 1):417.
  11.Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007;35(1):9-6.View Article PubMed
  12.Hoy SM. Peginterferon beta-1a: a review of its use in patients with relapsing–remitting multiple sclerosis. CNS Drugs. 2015;29(2):171-.View Article PubMed
  
• 作者单位：Katherine A. Lyseng-Williamson (1)
  Sheridan M. Hoy (1)
  
  1. Springer, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
  
• 刊物主题：Pharmacy; Pharmacotherapy;
• 出版者：Springer International Publishing
• ISSN：1179-1977

文摘

Peginterferon beta-1a (Plegridy? extends the options currently available to treat adults with relapsing–remitting multiple sclerosis (RRMS). Peginterferon beta-1a 125?μg every 2?weeks significantly reduced the adjusted annualized relapse rate, reduced the risks of relapse and sustained disability progression, and improved measures of disease activity relative to placebo at week 48 of the key 96-week phase 3 trial. The efficacy of peginterferon beta-1a appeared to be sustained with longer-term treatment (i.e. for up to a total of 96?weeks) in the subsequent 48-week non-controlled phase of the trial. The tolerability profile of peginterferon beta-1a is acceptable and consistent with those of established interferon beta treatments. The administration regimen of subcutaneous peginterferon beta-1a (every 2?weeks) provides potential compliance advantages over non-pegylated interferon beta formulations that require more frequent administration.